Results 51 to 60 of about 328,224 (217)

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro, Shiwen Koay, Gordon T. Ingle, Patricia McNamara, Laura Watson, Fion Bremner, Valeria Iodice   +6 more
wiley   +1 more source

Neurological complications of immune checkpoint inhibitor therapy: a multidisciplinary case review

Неврология, нейропсихиатрия, психосоматика
Immunotherapy using immune checkpoint inhibitors (ICIs) has demonstrated efficacy in treating a wide range of oncological diseases, but the use of this group of drugs is associated with the risk of developing serious immune-related adverse events (irAEs).
I. Yu. Oganesyan, V. V. Nazarova, O. N. Voskresenskaya, Z. R. Magomedova, D. E. Prokhorov, K. V. Orlova, A. R. Apevalova, A. E. Akhmetianova, Sh. R. Nabiev   +8 more
doaj   +1 more source

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito, Kamal Benguerba, Ken Tsuchida, Kazushige Yazawa, Isao Tsumiyama, Hiromitsu Kayama, Sandra P. Reyna, Farid Khan, Richard S. Finkel   +8 more
wiley   +1 more source

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors

Zhongliu Fangzhi Yanjiu, 2020
Immune checkpoint inhibitors(ICIs) has revolutionized the treatment of cancer. However, with the rapid application of CPIs, the immune-related adverse events (irAE) have attracted more and more attention.
ZHANG Xue, LI Dake
doaj   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source

Clinical and Modifiable Factors Associated With Disability and Relapse in MOGAD: A Multicentre Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Factors associated with relapse course and disability in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) remain incompletely understood. Objectives To identify clinical and modifiable factors associated with relapse and disability in MOGAD. Methods In this ambispective multicentre cohort study using data from
Yingtao Wang, Shaoxin Tao, Qiujia Wang, Xiaoyu Xu, Hui Yao, Zheng Liu, Dawei Li, Zhandong Qiu, Jinming Han, Jiangwei Xia, Qi Wang, Jun Sun, Kai Shao, Jiao Li, Shishuang Ruan, Yi Zhong, Jun Guo, Shougang Guo, Yue Huang, Guoliang Chai, Tao Jin, Hongyu Zhou, Junwei Hao, Yinan Zhao   +23 more
wiley   +1 more source

Predictive Value of Composite Inflammatory Markers for Stroke Prognosis: A Prospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Novel composite inflammatory markers' role in stroke prognosis is understudied, and the best predictor is unclear, requiring further exploration. Objectives This study aimed to systematically evaluate the associations of 6 novel composite inflammatory markers on stroke prognosis.
Bing Wu, Jie‐Jie Li, Jing Jing, Jin‐Xi Lin, Xia Meng, Yong Jiang, Yong‐Jun Wang, Hong‐Qiu Gu   +7 more
wiley   +1 more source

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto, Dariia Kliushnikova, Richard Friedrich Radlberger, Sinan Yasaroglu, Tobias Moser, Andrea Harrer, Kitty Kratzer, Wolfgang Hitzl, Christiane Gradl, Martin Schmidauer, Patrick Roth, Harald Hegen, Peter Wipfler   +12 more
wiley   +1 more source

Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether discontinuing anti‐CD20 therapy in people with relapsing‐onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.
Alexia Moukhine, Fabien Rollot, Romain Casey, Nicolas Collongues, Sandra Vukusic, Guillaume Mathey, Anne Laure Dubessy, Jonathan Ciron, Jérôme De Seze, Aurélie Ruet, Pierre Labauge, Arnaud Kwiatkowski, Hélène Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun‐Frenay, David Axel Laplaud, Eric Berger, Eric Thouvenot, Jean Pelletier, Abdullatif Al Khedr, Olivier Casez, Bertrand Bourre, Abir Wahab, Laurent Magy, Jean‐Philippe Camdessanché, Ines Doghri, Solène Moulin, Mariana Sarov Rivière, Karolina Hankiewicz, Amélie Dos Santos, Corinne Pottier, Eric Manchon, Jennifer Aboab, Maia Tchikviladze, Thomas David, Gilles Edan, Emmanuelle Le Page, Laure Michel, Anne Kerbrat, OFSEP Investigators   +40 more
wiley   +1 more source

Rheumatic Immune-related Adverse Events Induced by Immune Checkpoint Inhibitors: A Signal Detection Study Using the FAERS Database

Xiehe Yixue Zazhi
ObjectiveTo evaluate the occurrence of rheumatological immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) using real-world database data.MethodsBy searching the Food and Drug Administration Adverse Event Reporting System
KONG Wei, SHEN Juan, QIU Ji
doaj   +1 more source